This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/domain/vavai/projekt/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n6http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n19http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00209805%3A_____%2F10%3A%230000266%21RIV12-MZ0-00209805/
n17http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00209805%3A_____%2F10%3A%230000266%21RIV12-MZ0-00209805
rdf:type
n6:Vysledek skos:Concept
rdfs:seeAlso
http://synapse.koreamed.org/DOIx.php?id=10.5009/gnl.2010.4.S1.S82
dcterms:description
Background/Aims: To prospectively evaluate our palliative management of unresectable cholangiocarcinoma (CC) treated with tailored multimodal oncological therapy. Methods: Between January 2005 and January 2010, 50 consecutive patients with unresectable CC and jaundice were palliated with percutaneous drainage. Forty-three patients underwent metallic-stent implantation followed by brachytherapy. Patients were divided into two arms: the intra-arterial chemotherapy arm (IA arm, n=17) consisted of patients treated with locoregional treatment (IA admission of Cisplatin and 5-fluorouracil, or chemoembolization with Lipiodol) and/or systemic chemotherapy, while the systemic chemotherapy arm (IV arm, n=23) included all the other patients, who were treated only with systemic chemotherapy. Results: In total, 78 metal self-expandable stents were placed. Hilar involvement with mass-forming and periductal infiltrating types of CC (84%) was predominant. The average number of percutaneous interventional procedures was 11.61 per patient (range, 4-35). The median overall survival from diagnosis of disease for all patients was 13.5 months (range, 11.0-18.8 months). The median overall survival times were 25.2 months (range, 15.2-31.3 months) and 11.5 months (range, 8.5-12.6 months) in the IA and IV arms, respectively (p<0.05). The 1-, 2-, and 3-year survival rates in the IA and IV arms were 88.2%, 52.9%, and 10.1% and 43.5%, 25.4, and 0%, respectively. There were no major complications (WHO III/IV) due to interventional procedures. Conclusions: We could reach acceptable prognosis in patients with unresectable CC using complex tailored oncological therapy. However, the main limitations of prolonging survival are performance status, patient compliance and the maintaining of biliary tract patency Background/Aims: To prospectively evaluate our palliative management of unresectable cholangiocarcinoma (CC) treated with tailored multimodal oncological therapy. Methods: Between January 2005 and January 2010, 50 consecutive patients with unresectable CC and jaundice were palliated with percutaneous drainage. Forty-three patients underwent metallic-stent implantation followed by brachytherapy. Patients were divided into two arms: the intra-arterial chemotherapy arm (IA arm, n=17) consisted of patients treated with locoregional treatment (IA admission of Cisplatin and 5-fluorouracil, or chemoembolization with Lipiodol) and/or systemic chemotherapy, while the systemic chemotherapy arm (IV arm, n=23) included all the other patients, who were treated only with systemic chemotherapy. Results: In total, 78 metal self-expandable stents were placed. Hilar involvement with mass-forming and periductal infiltrating types of CC (84%) was predominant. The average number of percutaneous interventional procedures was 11.61 per patient (range, 4-35). The median overall survival from diagnosis of disease for all patients was 13.5 months (range, 11.0-18.8 months). The median overall survival times were 25.2 months (range, 15.2-31.3 months) and 11.5 months (range, 8.5-12.6 months) in the IA and IV arms, respectively (p<0.05). The 1-, 2-, and 3-year survival rates in the IA and IV arms were 88.2%, 52.9%, and 10.1% and 43.5%, 25.4, and 0%, respectively. There were no major complications (WHO III/IV) due to interventional procedures. Conclusions: We could reach acceptable prognosis in patients with unresectable CC using complex tailored oncological therapy. However, the main limitations of prolonging survival are performance status, patient compliance and the maintaining of biliary tract patency
dcterms:title
Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma
skos:prefLabel
Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma
skos:notation
RIV/00209805:_____/10:#0000266!RIV12-MZ0-00209805
n3:aktivita
n15:V n15:P n15:I
n3:aktivity
I, P(NT11128), V
n3:cisloPeriodika
1
n3:dodaniDat
n14:2012
n3:domaciTvurceVysledku
n8:7721706 n8:1012010 n8:1928260
n3:druhVysledku
n4:J
n3:duvernostUdaju
n12:S
n3:entitaPredkladatele
n19:predkladatel
n3:idSjednocenehoVysledku
273142
n3:idVysledku
RIV/00209805:_____/10:#0000266
n3:jazykVysledku
n18:eng
n3:klicovaSlova
cholangiocarcinonna; brachytherapy; Infusions; ntra-arterial; stents
n3:klicoveSlovo
n11:brachytherapy n11:stents n11:cholangiocarcinonna n11:ntra-arterial n11:Infusions
n3:kodStatuVydavatele
KR - Korejská republika
n3:kontrolniKodProRIV
[950EDC69E7BF]
n3:nazevZdroje
Gut and liver
n3:obor
n13:FD
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
7
n3:projekt
n16:NT11128
n3:rokUplatneniVysledku
n14:2010
n3:svazekPeriodika
4
n3:tvurceVysledku
Tuček, Štěpán Válek, Vlastimil Kiss, Igor Šlampa, Pavel
n3:wos
000281932700013
s:issn
1976-2283
s:numberOfPages
7
n17:doi
10.5009/gnl.2010.4.S1.S82